Form 4: NKGen Biotech Director Gottardis Grants Power of Attorney, Receives Stock Options

Marco Gottardis, a director at NKGen Biotech, granted power of attorney for SEC filings and received 300,000 stock options.

Summary

• Marco Gottardis, a director of NKGen Biotech, has granted power of attorney to several individuals for SEC filings related to beneficial ownership of securities.
• He appointed Jeremy Spankowski, Robbie Oakes, Jesse Dowdle, Mike Blankenship, and Pierre Gagnon to prepare and submit SEC filings on his behalf.
• This includes Form ID applications and statements of beneficial ownership on Schedule 13D and Forms 3, 4, and 5.
• Gottardis also received 300,000 stock options on July 11, 2024, under the company's 2023 Equity Incentive Plan.
• The options vest in equal monthly installments starting July 11, 2024, and ending July 11, 2027, contingent on continued service with NKGen Biotech.

Sentiment

Score: 7

Explanation: The document reflects standard corporate governance practices and incentivizes a director with stock options, which is generally viewed positively.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

Stock option grants are a common practice in the biotech industry to incentivize executives and align their interests with shareholders. The vesting schedule is typical for such grants.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in biotech companies.
• Vesting schedules of three to four years are common to ensure long-term commitment.
• Comparable companies such as Juno Therapeutics (acquired by Celgene) and Kite Pharma (acquired by Gilead) have used similar equity-based compensation strategies.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the director's interests with the company's long-term success.
• The director is incentivized to contribute to the company's growth and profitability.

Key Dates